Diretrizes

Recomendações da OMS para evitar danos auditivos em eventos.

8 Mar, 2022 | 17:33h

WHO global standard for safe listening venues and events – World Health Organization

Perguntas & Respostas: Deafness and hearing loss: Safe listening – World Health Organization

Comentários:

WHO Releases New Noise Standard for Public Venues to Tackle Hearing Loss – Health Polity Watch

Obesity rates likely to double by 2030 with highest rises in lower-income countries – The Guardian

Comentário no Twitter (fio – clique para saber mais)

Today is #WorldHearingDay!

1 in 2 young people are is at risk of hearing loss from prolonged and excessive exposure to loud music and other recreational sounds.

Find out how you can protect your hearing https://t.co/0bvXNbYgFw #SafeListening

— World Health Organization (WHO) (@WHO) March 2, 2022

Novo World Obesity Atlas alerta para a projeção de que, em 2030, mais de 1 bilhão de pessoas viverão com obesidade.

8 Mar, 2022 | 17:20h

Comentário: Over 1 Billion People Projected to Live with Obesity by 2030, Warns New World Obesity Atlas – Health Policy Watch

Relatório: Obesity Atlas 2022 – Global Obesity Observatory

Diretrizes WSES sobre lesão intestinal contusa e penetrante: diagnóstico, investigações e tratamento.

8 Mar, 2022 | 17:18h

WSES guidelines on blunt and penetrating bowel injury: diagnosis, investigations, and treatment – World Journal of Emergency Surgery

Recomendações WSES/GAIS/WSIS/SIS-E/AAST para pacientes com infecções cutâneas e de partes moles.

8 Mar, 2022 | 17:17h

WSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients with skin and soft tissue infections – World Journal of Emergency Surgery

Diretriz atualizada da OMS recomenda condicionalmente o molnupiravir para pacientes com Covid-19 não grave sob alto risco de internação.

8 Mar, 2022 | 16:14h

Comunicado de imprensa BMJ: WHO recommends antiviral drug for patients with non-severe covid-19 at highest risk of hospital admission – BMJ

Comunicado de imprensa OMS: WHO updates its treatment guidelines to include molnupiravir

Ver diretriz atualizada: A living WHO guideline on drugs for covid-19 – BMJ

Conteúdos relacionados:

Editorial (recém-publicado): Molnupiravir’s authorisation was premature – The BMJ

RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.

Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Diretrizes ACR para o tratamento da artrite idiopática juvenil.

8 Mar, 2022 | 16:01h

Comunicado de imprensa: The American College of Rheumatology releases two updated guidelines for treatment of juvenile idiopathic arthritis – American College of Rheumatology

2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging – Arthritis & Rheumatology

2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis

Diretriz para acompanhamento ambulatorial do controle glicêmico em pessoas com câncer.

8 Mar, 2022 | 15:59h

A guideline for the outpatient management of glycaemic control in people with cancer – Diabetic Medicine

Relatório clínico AAP | Reconhecimento e tratamento da insuficiência cardiovascular no neonato de muito baixo peso ao nascer.

8 Mar, 2022 | 15:58h

Recognition and Management of Cardiovascular Insufficiency in the Very Low Birth Weight Newborn – Pediatrics

Atualização da diretriz JCS/JHRS focada em terapias não farmacológicas das arritmias cardíacas.

8 Mar, 2022 | 15:57h

JCS/JHRS 2021 guideline focused update on non-pharmacotherapy of cardiac arrhythmias – Journal of Arrythmia

OMS | Pandemia de COVID-19 desencadeou um aumento de 25% na prevalência de ansiedade e depressão ao redor do mundo.

3 Mar, 2022 | 16:55h

Comunicado de imprensa: COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide – World Health Organization

Resumo científico: Mental health and COVID-19: Early evidence of the pandemic’s impact – World Health Organization